Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs

American Journal of Therapeutics

Volumn 13, Issue 2, 2006, Pages 134-140

  Johnsen, S P ^a,b   Monster, T B M ^a   Olsen, M L ^a   Thisted, H ^a,b   McLaughlin, J K ^c,d   Sorensen H T ^a,d   Lervang, H H ^b   Rungby, J ^b,e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Antidiabetic drugs; Epidemiology; Myocardial infarction; Sulfonylurea

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NITRATE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; CONFIDENCE INTERVAL; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; POPULATION; PRESCRIPTION; RISK; RISK ASSESSMENT; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DENMARK; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; POPULATION; PRESCRIPTIONS, DRUG; PROGNOSIS; RISK ASSESSMENT; SULFONYLUREA COMPOUNDS;

EID: 33646537772     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200603000-00009     Document Type: Article

References (26)

1. Ghosh S, Standen NB, Galiñanes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol. 2001;37:711-718.
2. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol. 1998;31:950-956.
3. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res. 1995;77:1030-1035.
4. Berger M, Mühlhauser I, Sawicki PT. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease [Letter]. Diabetologia. 1998;41:744.
5. Cleveland JC, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischaemic preconditioning in human myocardium. Two paradoxes revisited. Circulation. 1997;96:29-32.
6. + channel blocker. Circulation. 1994;90:700-705.
7. Klepzig H, Kober G, Matter C, et al. Sulphonylureas and ischaemic preconditioning. A double blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999;20:439-446.
8. Lee T-M, Chou T-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531-537.
9. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from β cells and extrapancreatic tissues. Metabolism. 2000;10:3-6.
10. ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001;44:1019-1025.
11. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19:789-830.
12. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J. 1999;138:S346-S352.
13. Prospective Diabetes Study UK (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
14. Davis TME, Parsons RW, Broadhurst RJ, et al. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relation to diabetes treatment. Diabetes Care. 1998;21:637-640.
15. Gustafsson I, Hildebrandt P, Seibaek M, et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. Eur Heart J. 2000;21:1937-1943.
16. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33:119-124.
17. Jollis JG, Simpson RJ, Cascio WE, et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J. 1999;138:S376-S380.
18. Danchin N, Charpentier G, Ledru F et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev. 2004; early online publication July 28, 2004.
19. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. Dan Med Bull. 1999;46:263-268.
20. Wacholder S, McLaughlin JK, Silverman DT, et al. Selection of controls in case-control studies. I. Principles. Am J Epidemiol. 1992;135:1019-1028.
21. Madsen M, Balling H, Eriksen LS. Validiteten af diagnosen akut myokardieinfarkt i to registre: Hjerteregisteret sammenlignet med Landspatientregisteret. [The validity of the diagnosis of acute myocardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry] Ugeskr Laeger. 1990;152:308-314.
22. Nielsen GL, Sørensen HT, Pedersen AB, et al. Analyses of data quality in registries concerning diabetes mellitus: a comparison between a population based hospital discharge and an insulin prescription registry. J Med Syst. 1996;20:1-10.
23. Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet. 2004;364:423-428.
24. Harrower ADB. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22:313-320.
25. Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism. 2000;10:17-20.
26. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244-2248.